Dual-labeling with 5–aminolevulinic acid and fluorescein for fluorescence-guided resection of high-grade gliomas: technical note

Eric Suero Molina, Walter Stummer(University of Münster), Johannes Wölfer(University Hospital Münster), Benjamin Brokinkel(University Hospital Münster), André Ehrhardt(Karl Storz (Germany)), Christian Ewelt(University of Münster)
Journal of neurosurgery
March 24, 2017
10.3171/2016.11.jns161072
Cited by 61

Related Papers

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
|The Lancet Oncology|2006|3.4k
EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME
|Neurosurgery|2008|1k
Fluorescence-guided resection of glioblastoma multiforme utilizing 5-ALA-induced porphyrins: a prospective study in 52 consecutive patients
|Journal of neurosurgery|2000|880
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
|The Lancet|2019|581
What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas?
|Neurosurgery|2015|368